Neurosoft Bioelectronics, a Swiss neurotechnology company working on next-generation brain-computer interfaces, has raised $7.5 million in an oversubscribed seed funding round. The fresh capital will support the company’s efforts to advance its minimally invasive brain interface technology and expand clinical development programs.
Strong investor interest in neurotechnology
The seed round attracted strong participation from multiple investors. It was led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations.
The round was oversubscribed, showing high investor demand for the company’s approach to brain-computer interface (BCI) systems. The total funding raised by Neurosoft Bioelectronics now stands at more than $20 million.
Building soft and flexible brain interfaces
Neurosoft Bioelectronics develops soft, stretchable brain-computer interfaces designed to sit on the surface of the brain rather than penetrate brain tissue.
Unlike traditional implantable neural devices, the company’s system focuses on a minimally invasive design. The technology uses flexible materials that can conform to the brain’s surface while recording neural signals across a wide area of the cortex.
This approach aims to improve both safety and long-term usability, two major challenges in current brain implant technologies.
Early human testing and clinical expansion
The company has already tested its technology in early human studies involving a small group of patients. Reports indicate that around 10 patients have been involved in initial testing of its brain interface system.
Neurosoft Bioelectronics is now preparing to expand clinical trials in the United States and Europe. The newly raised funds will help support this expansion, along with continued development of its neural interface platform.
Focus on next-generation brain technology
The startup is working toward improving how brain signals are captured and interpreted, with the long-term goal of supporting better treatment and understanding of neurological conditions.
By focusing on soft, flexible materials and less invasive designs, the company aims to make brain-computer interface technology more practical for real-world medical use.
With its $7.5 million seed round, Neurosoft Bioelectronics is moving forward in the rapidly growing field of neurotechnology. Strong investor backing and early clinical progress position the company to advance its vision of safer and more scalable brain-computer interface systems.
